Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00988208 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,059
- Enrollment target
NCT00988208: Completed Phase 3 study, sponsored by Celgene.
NCT00988208 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 1,059 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00988208, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,059 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether lenalidomide is safe and effective for use in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer. The addition of lenalidomide to docetaxel and prednisone is proposed to increase the life expectancy of these subjects.
Primary Outcome
Overall survival (OS) was the time from the date of randomization to the date of death from any cause. If no death was reported for a participant before the cut-off date for OS analysis, OS was censored at the last date at which the participant was alive. The median OS was calculated based on Kaplan-Meier estimates and corresponding 95% confidence interval (CI) was calculated using the method provided by Brookmeyer and Crowley.
Interventions
- DRUG Placebo
- DRUG Docetaxel
- DRUG Lenalidomide
- DRUG Prednisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,059 participants |
| Start Date | 2009-11-11 |
| Est. Completion | 2016-11-28 |
| Phase | Phase 3 |
What the finished NCT00988208 record still lists
NCT00988208 is an interventional study that assigns participants to a tested intervention. Its 1,059 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00988208 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00988208 about?
NCT00988208 is a clinical study titled "Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer". The purpose of the study is to determine whether lenalidomide is safe and effective for use in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer. The addition of lenalidomide to docetaxel and prednisone is proposed to increase...
What is the current status of trial NCT00988208?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,059 participants. The study started on 2009-11-11. Estimated completion is 2016-11-28.
What interventions are being tested in trial NCT00988208?
The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), Lenalidomide (DRUG), Prednisone (DRUG).
Who is sponsoring clinical trial NCT00988208?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00988208's enrollment target sits among peer trials
1,059 275th of 2000 higher than 1,725 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05125302 · 1,059 participants · Phase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
- NCT05911568 · 1,060 participants
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
- NCT07140172 · 1,060 participants · NA
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI